Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Modification of Imatinib to Other Tyrosine Kinase Inhibitors Dependent on 3-months Molecular Response of CML Patients

NCT01762969 is registered in ClinicalTrials.gov with Rabin Medical Center as lead sponsor.

NCT NCT01762969
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01762969 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Modification of Imatinib to Other Tyrosine Kinase Inhibitors Dependent on 3-months Molecular Response of CML Patients
Lead sponsor
Rabin Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2013
Completion date
January 31, 2020
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cml